SOURCE: StockCall

StockCall

May 27, 2011 08:50 ET

Analyst Research on Gilead Sciences Inc. and Human Genome Sciences Inc. -- Biotechnology Sector Benefits When Regulators Say 'OK'

JOHANNESBURG, SOUTH AFRICA--(Marketwire - May 27, 2011) - www.stockcall.com/ offers investors comprehensive research on the Biotechnology industry and has completed analytical research on Gilead Sciences Inc. (NASDAQ: GILD) and Human Genome Sciences Inc. (NASDAQ: HGSI). Register with us today at www.stockcall.com/ to have free access to these researches.

The biotechnology and pharmaceutical sectors are usually quite diverse and company specific in their happenings. The success of each company depends on a wide range of independent factors along with their ability to acquire regulatory approval for marketing and selling drugs. A good example of this can be seen in the recent news surrounding Gilead Sciences Inc. and Human Genome Sciences Inc. Register now at https://stockcall.com/development/stockcall/page.php?name=register.html to have free access to our reports on the Biotechnology industry.

www.stockcall.com/ is an online platform where investors doing their due-diligence on the Biotechnology industry can have easy and free access to our analyst research and opinions on Gilead Sciences Inc. and Human Genome Sciences Inc.; all investors need to do is register for a complimentary membership at https://stockcall.com/development/stockcall/page.php?name=register.html.

Gilead Sciences has been dealing with protestors that want the company to lower its prices for AID's medication programs in the United States. All companies that make treatments typically walk the high wire between fiscal success and public altruism. The company, a major player in the HIV market, recently has been developing a drug with great efficacy at preventing the transmission of the disease between partners. Investors looking for free research on Gilead Sciences Inc. are welcome to sign up at www.stockcall.com/GILD270511.pdf for our new report.

In this sector, what is good for patients is also good for the pocketbooks. For Human Genome, the big news lately has been the European approval of human use for their Lupus Drug, Benlysta-belimumab. Regulatory approval is usually the pay off for large amounts of time and money invested in developing a product as now it can be put on the market and begin accruing revenue. Investors looking for complimentary research on Human Genome Sciences Inc. are welcome to sign up at www.stockcall.com/HGSI270511.pdf for our new report.

Visit www.stockcall.com/ to see how companies in this industry have grown over the past years and how they are expected to perform in the future.

About StockCall.com
StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.

Contact Information